INJ Price Stalls Despite Robinhood Listing as Traders Watch $5 Breakout

Exchange listings and popular trading app platform like Robinhood have often been treated like instant fuel for crypto rallies. This time, though, the market barely blinked. INJ price showed little reaction after Robinhood officially listed Injective alongside USDC and other assets, a sharp contrast to how other assets usually react when any assets listing news are announced.

Robinhood Listing Gets Muted Market Response

Today, Robinhood on X announced that users can now trade INJ on one of the largest U.S.-based crypto platforms. Despite the milestone, the token failed to deliver the kind of price surge traders have come to expect from major listings.

That’s a noticeable shift. Earlier similar listing news for any token from South Korea’s Upbit has mostly triggered a parabolic rally, but this latest announcement has generated only a limited response. At least for now, the market appears reluctant to price in the listing immediately.

Still, the development shouldn’t be dismissed entirely. While speculative momentum has been missing, broader accessibility through Robinhood could gradually improve long-term demand as more retail participants gain exposure to the asset.

Recovery Trend Still Faces Technical Barrier

The broader INJ price structure remains more important than the listing headline itself. After bottoming near $3 in April, the token rallied to roughly $7.30 by early June before running into strong resistance.

That rejection pushed the price back toward the $4 region by late June, leaving Injective Injective Injective is a layer-1 blockchain built for decentralized finance (DeFi). It powers Web3 apps like decentralized exchanges (DEXs), derivatives trading, and cross-chain markets, with a clear focus on finance. Injective runs on Cosmos SDK and Tendermint Proof-of-Stake (PoS), which helps it offer fast transactions, low fees, and quick finality. It also has a fully decentralized on-chain orderbook and supports cross-chain interoperability, making it useful for DeFi and crypto trading. Injective Labs also supports network security and growth through validator operations and protocol development.  Key Features of Injective:   Handles 10,000+ transactions per second with almost instant finality. Run by the community using the INJ token for voting. Features a decentralized on-chain order book (CLOB) for transparent trading. Uses batch auctions (FBA) to reduce front-running and keep trading fair.   Injective Milestones:   Year Key Achievements 2018 Injective Protocol was launched by Albert Chon and Eric Chen. Selected for the Binance Labs incubation program. 2019 Launch of the first version of the on-chain order book and decentralized derivatives products. 2020 Funding round from Pantera Capital.  Public token sale via Binance Launchpad. Launch of the Solstice Testnet for synthetic assets. 2021 Launch of Injective Mainnet with Peggy Bridge and IBC integration.  Introduction of Injective Hub and staking. Secured funding from Mark Cuban. 2022 Introduction of the CosmWasm smart contract layer.  Launch of Bridge V2. Integration of Wormhole to connect with Solana and other chains. 2023 Launch of a $150M Ecosystem Fund. Release of inEVM and inSVM as a multi-VM environment.  Partnership with Google Cloud for BigQuery integration. 2024 The Volan Mainnet Upgrade enables institutional RWA modules.    Event OrganiserTechnology in a consolidation phase rather than a confirmed uptrend.

Can INJ Price Clear The 200-Day EMA?

For bulls, the next challenge is straightforward. The INJ price needs to reclaim the 200-day EMA, positioned around the $5 level. A successful breakout could open the path toward $7, with a broader upside target near $14 if buying pressure strengthens.

Failure to regain that level, however, could invite fresh selling. In that scenario, the token risks revisiting the $3 support zone or potentially moving even lower as bearish pressure returns.

• INJ$ 5.09(0.77%)